CrossrefInfokarte
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated
Cancer Chemotherapy and Pharmacology · 2025-12 · 95 (1)
DOI: 10.1007/s00280-025-04802-8 ↗Abstract
Kein Abstract verfügbar.
EUVIMED